YAP1 and non-small cell lung carcinoma: A database linking drug data to genomic information has identified dasatinib and statin as a strategy to inhibit YAP1 in cancer cells.[44] Dasatinib, an FDA-approved drug for certain types and conditions of leukemia, has been reported to induce apoptosis in EGFR-dependent lung cancer cells.[45] Phase I/II and phase II clinical trials using dasatinib to treat NSCLC patients have been performed without specific selection and showed only modest effects.